Key result
Non-alcoholic fatty liver disease independently increases the risk for subclinical atherosclerosis, coronary artery disease, hypertension, cardiac remodeling, arrhythmias, and heart failure.
Why the study?
Mortality in NAFLD is driven primarily by cardiovascular complications rather than liver disease progression, warranting an evaluation of pathophysiological links and clinical effects on the heart and blood vessels.
Highlights the critical need for early cardiovascular risk assessment in patients with NAFLD and consideration of liver pathology when treating cardiovascular diseases.
In recent years, non-alcoholic fatty liver disease (NAFLD) has been associated with metabolic syndrome (MetS) and is considered as one of its components. The mortality rate of patients with NAFLD is due not so much to the progression of liver damage as to cardiovascular complications. This review summarizes current data on possible pathophysiological mechanisms linking NAFLD and cardiovascular diseases. The article analyzes the clinical effects of NAFLD on the heart and blood vessels: atherosclerosis, myocardial remodeling, rhythm and conduction disorders, and chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Salikova et al. (2020) conducted a review in Non-alcoholic fatty liver disease and metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) was evaluated. Non-alcoholic fatty liver disease independently increases the risk for subclinical atherosclerosis, coronary artery disease, hypertension, cardiac remodeling, arrhythmias, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: